Evidence map›Paper›PMID 40601170›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Two-hit events occurred independently in bilateral breast cancers in a germline double heterozygous carrier for BRCA1 and BRCA2.

Ryoko Semba, Hidetaka Eguchi, Mizuki Takatsu, Toko Hashizume, Hideaki Moteki, Kazuma Maeno, Fumi Murakami, Junichiro Watanabe, Goro Kutomi, Masami Arai

Abstract readCase Reports
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryoko SembaDepartment of Breast Surgery, Juntendo University Nerima Hospital, Takanodai 3-1-10, Nerima-Ku, Tokyo, 177-8521, Japan.
Hidetaka EguchiDiagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mizuki TakatsuDepartment of Clinical Genetics, Aizawa Hospital, Matsumoto, Japan.
Toko HashizumeDepartment of Breast and Thyroid Surgery, Aizawa Hospital, Matsumoto, Japan.
Hideaki MotekiDepartment of Clinical Genetics, Aizawa Hospital, Matsumoto, Japan.
Kazuma MaenoDepartment of Breast and Endocrine Surgery, Suwa Red Cross Hospital, Suwa, Japan.
Fumi MurakamiDepartment of Breast Surgery, Juntendo University Nerima Hospital, Takanodai 3-1-10, Nerima-Ku, Tokyo, 177-8521, Japan.
Junichiro WatanabeDepartment of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Goro KutomiDepartment of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Masami AraiDepartment of Breast Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan. ms-arai@juntendo.ac.jp.ORCID http://orcid.org/0000-0001-7544-4536

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While patients with hereditary breast and ovarian cancer with germline double heterozygosity (GDH) for BRCA1 and BRCA2 are rare, carcinogenesis in these cases remains unclear. We examined two-hit events of heterochronous bilateral breast cancers in a patient with GDH for BRCA1 and BRCA2. A 65-year-old woman developed right breast cancer (triple-negative type) at the age of 49 and left breast cancer (triple-negative type) at 55. Family history indicated that multiple relatives on her mother's side also developed breast cancer. BRCA1/2 genetic testing (BRACAnalysis®) showed that she had variants in both the BRCA1 and BRCA2 (BRCA1:c.5193 + 2dup, BRCA2:c.6952C > T/p.Arg2318Ter). According to the data from the test, the former was interpreted as likely pathogenic at Myriad Inc. Further examination regarding two-hit events in her bilateral breast cancers was obtained by somatic mutation analysis using DNA isolated from cut slide specimens of formalin-fixed and paraffin-embedded tumor samples. We first confirmed the pathogenicity of the BRCA2 variant by detecting unusual splicing of BRCA2 that entirely skipped exon 19 using cultured T cells of the proband. Loss of heterozygosity in BRCA1 was observed in her right breast cancer. On the other hand, a somatic nonsense pathogenic variant in BRCA2 (variant allele frequency = 15%) and a two-hit event in APC (VAF = 80%) were also found in her left breast cancer. These data provide evidence of different carcinogenesis between left and right breast cancer. Clinical and pathogenic characteristics of cancers with GDH for BRCA1 and BRCA2 depend on the genes somatically mutated in wild alleles.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsGerm-Line MutationTriple Negative Breast NeoplasmsAgedFemaleGenetic Predisposition to DiseaseHeterozygoteHumansLoss of HeterozygosityMiddle AgedPedigreeBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1 and BRCA2Breast cancerDouble heterozygosityHereditary breast and ovarian cancerTwo-hit events

Identifiers

PMID40601170
PMCPMC12552342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.